.png "Global Blood Therapeutics (NASDAQ: GBT)")
In a report released today, Ritu Baral from Cowen & Co. maintained a Buy rating on Global Blood Therapeutics (GBT), with a price target of $83. The company’s shares opened today at $49.30.
According to TipRanks.com, Baral is a top 100 analyst with an average return of 22.4% and a 47.9% success rate. Baral covers the Healthcare sector, focusing on stocks such as Milestone Pharmaceuticals Inc, ACADIA Pharmaceuticals Inc, and Allena Pharmaceuticals Inc.
Currently, the analyst consensus on Global Blood Therapeutics is a Strong Buy with an average price target of $93.22, representing an 89.1% upside. In a report released yesterday, William Blair also maintained a Buy rating on the stock.
See today’s analyst top recommended stocks >>
The company has a one-year high of $64.94 and a one-year low of $30.15. Currently, Global Blood Therapeutics has an average volume of 938K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. It also provides oral medicines for sickle cell diseases.
